ArticleBMC musculoskeletal disorders2019
Aneurysmal bone cyst: results of an off label treatment with Denosumab.
Article in BMC musculoskeletal disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review.Archives of endocrinology and metabolism · 2024Pooled it
- Management of juvenile and aneurysmal bone cysts: a systematic literature review with meta-analysis.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2023Pooled it
- Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study.The oncologist · 2023Trial
- The best solution is the simplest: advances in surgical and minimally invasive management of aneurysmal and simple bone cysts.Journal of orthopaedic surgery and research · 2026Review
- Significant Response to Denosumab Yet with Severe Rebound Hypercalcemia in a 9-Year-Old Boy with Aneurysmal Bone Cyst: A Case Report.Children (Basel, Switzerland) · 2025Article
- Resection and 3D-printed prosthetic reconstruction of a giant aneurysmal bone cyst in the atlas: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Rethinking the role of bisphosphonates after denosumab treatment in locally advanced or unresectable aneurysmal bone cysts: A meta-analysis.World journal of orthopedics · 2025Article
- Article
- Primary Aneurysmal Bone Cyst of Sacrum: A Case Report of a 12 years old boy from Pakistan.Pakistan journal of medical sciences · 2024Article
- A Short Course of Preoperative Denosumab Injection Followed by Surgery in High-Risk Giant Cell Tumors of the Extremities: A Retrospective Study.Indian journal of surgical oncology · 2024Article
- Sclerotherapy with absolute alcohol in a child with spinal aneurysmal bone cyst: A case report.Radiology case reports · 2024Article
- Review
- Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document.The Journal of clinical endocrinology and metabolism · 2024Article
- Using Denosumab as a Nonsurgical Management of Aneurysmal Bone Cysts in the Pelvis.Clinics in orthopedic surgery · 2024Article
- Current indications for denosumab in benign bone tumours.EFORT open reviews · 2023Review
- Diagnostic Approach and Differences between Spinal Infections and Tumors.Diagnostics (Basel, Switzerland) · 2023Review
- Article
- Surgical Management and Denosumab for Aneurysmal Bone Cysts of the Spine in an Australian Tertiary Paediatric Centre.Calcified tissue international · 2023Article
- Treatment of benign bone lesions with an injectable biphasic bone substitute.BMC musculoskeletal disorders · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe treatment of aneurysmal bone cysts (ABCs) has evolved and less invasive methods have been tried. Denosumab is a monoclonal antibody which inhibits osteoclasts. It has been shown to be effective in giant cell tumour of bone (GCT) of bone and hence promises some effect also in ABC. We report on 6 patients treated with Denosumab and compare our results to the cases already published.
methodsData of 6 patients with ABCs and patients whose treatment included Denosumab were retrospectively analyzed. Denosumab was used at a dose of 120 mg on days 1, 8, 15 and 29, and every 4 weeks thereafter. In some of these patients the dose was reduced at the end of the treatment. Clinical and radiological responses were evaluated.
resultsIn 4 female and 2 male patients with a mean age of 17 years (range: 6-30 years) the lesions were located in the sacrum (2), in distal radius, distal femur, talus and pelvis. One of the sacral lesions healed after 12 months and has stayed stable for 3 years since. The second patient received 2 years of therapy with recalcification, but recurred 1 year later and is under renewed therapy. The pelvic lesion improved but recurred. This patient has a 13-years history of intermittent therapy including surgery, two pregnancies and remains in a stable situation. The lesion of the talus did not improve with Denosumab after surgery and was complicated by destruction of the ankle joint with osteoarthritis. Recurrent lesions of the distal femur and the distal radius, previously treated by curettage and bone grafting healed under Denosumab and have remained stable for 2 and 3 years, respectively. One case of severe hypercalcemia was observed in a 7-year old child 6 months after discontinuation of Denosumab.
conclusionDenosumab provides a treatment option for ABCs in anatomically critical locations. Adjuvant application might reduce the rate of local recurrence. In young patients, severe rebound hypercalcemia months after discontinuation of Denosumab may occur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.